FDA approves idecabtagene vicleucel for triple-class-exposed RRMM
On April 5, 2024, the U.S. FDA granted approval to idecabtagene vicleucel for the treatment of triple-class-exposed relapsed/refractory multiple myeloma after two or more prior therapies, including an immunomodulatory agent, proteasome inhibitor, and an anti-CD38 antibody.